Akari Therapeutics, Plc Holds Special General Meeting: Key Shareholder Votes on Warrants and Share Issuances
Key Highlights
- Date of Event: March 2, 2026
- Event: Special General Meeting of Shareholders
- Key Matters: Approval of exercisability of various warrants and related share issuances in connection with recent financings and note exchanges
- Shareholder Participation: Proxies were solicited, and shareholder votes were recorded for each resolution
Resolutions and Voting Results
At the Special General Meeting, shareholders of Akari Therapeutics, Plc were asked to approve several resolutions related to the exercisability of warrants and the issuance of American Depositary Shares (ADSs) and ordinary shares underlying such warrants. These approvals were required to comply with Nasdaq Listing Rules following recent financing activities. The outcome of these votes is crucial, as they affect potential dilution, capital structure, and the company’s ability to raise future capital, all of which can be price-sensitive for investors.
1. Approval of Series G and Placement Agent Warrants (Registered Direct Offering & Concurrent Private Placement)
- Purpose: To approve, for Nasdaq compliance, the exercisability of:
- Series G Warrants to purchase up to 10,043,774 ADSs
- Placement Agent Warrants to purchase up to 504,300 ADSs
and the issuance of the underlying ADSs and ordinary shares.
- Background: These warrants were issued in connection with a registered direct offering and a concurrent private placement that closed on December 17, 2025 and January 20, 2026.
- Potential Share Price Impact: Approving these warrants enables additional share issuance, potentially increasing the float and impacting share price through dilution, but also reflecting confidence in the company’s financing strategy.
2. Approval of Pre-Funded and Series G Warrants (Private Placement Closing December 23, 2025)
- Purpose: To approve, for Nasdaq compliance, the exercisability of:
- Pre-Funded Warrants to purchase up to 2,563,713 ADSs
- Series G Warrants to purchase up to 2,563,713 ADSs
and the issuance of the underlying shares.
- Background: These warrants were issued in connection with a private placement closing on December 23, 2025.
- Voting Results:
- For: 40,370,370,401
- Against: 308,000,000
- Abstain: 8,652,000
- Broker Non-Votes: 0
- Potential Share Price Impact: Approval allows for further potential share issuance and capital inflow, but also increases dilution risk.
3. Approval of Pre-Funded and Note Exchange Warrants (Exchange of Notes – December 17, 2025)
- Purpose: To approve, for Nasdaq compliance, the exercisability of:
- Pre-Funded Warrants to purchase up to 4,673,963 ADSs
- Note Exchange Warrants to purchase up to 4,673,963 ADSs
and the issuance of the underlying shares.
- Voting Results:
- For: 40,371,562,401
- Against: 308,002,000
- Abstain: 7,458,000
- Broker Non-Votes: 0
- Potential Share Price Impact: Approval may result in more shares being issued, affecting the supply of shares and price dynamics, while providing the company with greater flexibility to restructure its capital.
4. Approval of Additional Pre-Funded and Note Exchange Warrants (Exchange of Notes – December 17, 2025)
- Purpose: To approve the exercisability of:
- Pre-Funded Warrants to purchase up to 9,502,703 ADSs
- Note Exchange Warrants to purchase up to 9,502,703 ADSs
and the issuance of the underlying shares.
- Voting Results:
- For: 40,444,976,401
- Against: 241,588,000
- Abstain: [Not specified]
- Potential Share Price Impact: Represents a significant authorization for potential share issuance, with implications for dilution, capital structure, and the company’s ability to finance operations or strategic initiatives.
Other Important Information
- Primary Trading Security: American Depositary Shares (ADSs), each representing 2,000 ordinary shares, trading on NASDAQ under the symbol AKTX.
- Ordinary Shares: Par value \$0.000000005 per share, not directly listed for trading, but underlying the ADSs.
- Emerging Growth Company: The company indicated it is not an emerging growth company and has not elected to use the extended transition period for complying with any new or revised financial accounting standards.
- Filing Status: The Form 8-K is not being used as written communication, soliciting material, or pre-commencement tender offer communication.
- Officer Signing: The report is signed by Kameel Farag, Interim Chief Financial Officer.
Why This News Matters to Investors
The approval of these resolutions by shareholders enables Akari Therapeutics, Plc to issue a substantial number of new shares in connection with previously agreed financing and note exchange transactions. While this enhances the company’s financial flexibility and ability to attract capital, it also introduces the risk of significant dilution for existing shareholders. The magnitude of the authorized share and warrant issuances could materially affect share value, trading dynamics, and investor sentiment.
Investors should closely monitor:
- The exercise and conversion of these warrants into shares
- Any subsequent capital raises or strategic transactions
- The company’s capital structure and potential for future dilution
- Announcements regarding the use of proceeds from these financings
Disclaimer
This article is for informational purposes only and does not constitute investment advice. Investors should conduct their own research and consult with a qualified financial advisor before making investment decisions. The information is based on the company’s SEC filing as of March 2, 2026, and may be subject to further updates or amendments.
